A research team led by Professor Bang Myung-gul from Korea University has notably published a study on carbon dots for central nervous system therapies in the high-impact journal Theranostics.
The research led by Professor Bang Myung-gul's team from the Animal Biotechnology Department at Korea University has been published in the journal Theranostics, recognized as one of the leading academic journals in the field of medicine. The paper, titled "Carbon dots penetrating the blood-brain barrier for central nervous system nanomedicine," proposes carbon dots (CDs) as a next-generation platform for the diagnosis and treatment of central nervous system diseases. These conditions remain some of the most challenging to treat, primarily due to the restrictive nature of the blood-brain barrier, which limits the movement of most therapeutic agents into brain tissue.
The research team comprehensively outlined strategies to enhance blood-brain barrier permeability and selective brain accumulation of ultra-small luminescent carbon nanoparticles. By employing surface modifications such as targeted ligands, polymer coatings, biomimetic membranes, and exosome-like structures, CDs can significantly increase their permeability through the blood-brain barrier and selectively accumulate in the brain. The intrinsic fluorescent properties of CDs and their tunable surface chemistry are highlighted as particularly advantageous features within the realm of precision nanomedicine.
Beyond targeted drug and gene delivery, CDs enable various imaging techniques such as fluorescence, magnetic resonance, and photoacoustic imaging, facilitating early diagnosis and real-time monitoring of therapeutic responses. Furthermore, their antioxidative, anti-inflammatory, photothermal, photodynamic, and ultrasound-mechanical properties allow for the implementation of integrated image-guided therapeutic methods. This combination of diagnostic and therapeutic capabilities underscores the potential of CDs in providing collaborative treatment strategies for central nervous system tumors and other neurological disorders. The paper also analyzes challenges for clinical applications, including issues of translation barriers, large-scale production, and long-term safety, while suggesting future research directions.
